Obesity Catalyst Calendar — Readouts and Decisions

Upcoming clinical readouts, regulatory decisions and company events in obesity drug development, in date order with sources.

• 2026 Q3 · Viking (VKTX) — VK2735 maintenance dosing study data Shows whether weight loss holds at a lower maintenance dose — the key question for real-world, long-term use, and a preview of the VANQUISH Phase 3.
• Aug 5, 2026 · Eli Lilly (LLY) & Novo Nordisk — Q2 2026 results on the same day - the quarter's key read on the obesity market Both leaders report together: oral Wegovy versus Foundayo uptake, and whether guidance moves.
• 2026 Q3 · Structure Therapeutics (GPCR) — Aleniglipron registrational Phase 3 start Positive end-of-Phase-2 FDA feedback; execution on this timeline matters most for the smallest oral challenger.
• 2026 H2 · Novo Nordisk — CagriSema FDA decision — first once-weekly GLP-1 + amylin combination for weight management ~23% weight loss — close to tirzepatide. Approval would put Novo back in the race; delay or rejection would deepen its lag behind Lilly.
• 2026 H2 · Eli Lilly (LLY) — Retatrutide - remaining Phase 3 readouts; BLA filing guided to Q1 2027 TRIUMPH-2 and -3 read out on Jul 23, 2026 (28.3% in TRIUMPH-1). The remaining readouts and the Q1 2027 filing set the next bar for the whole category.
• 2026 H2 · Zealand / Roche — Petrelintide + enicepatide combination Phase 2 start The amylin-based combo bets on tolerability; if it works, it offers a real alternative for patients sensitive to GLP-1 side effects — and validates Roche's $5.3B bet.
• 2026 H2 · Pfizer / Metsera — Berobenatide (MET-097i) Phase 3 programme - ten trials planned for 2026 After the Metsera deal this is the most significant new competitive entry into the incretin field.
• Late 2027 · Viking (VKTX) — VANQUISH-1 Phase 3 topline (~4,650 pts, 78 wks) — the main binary event Viking's decisive, binary readout. Success lifts VK2735 close to the market leaders; failure erases much of the thesis. One of the sector's biggest single risks.